{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:08:24Z","timestamp":1791331704961,"version":"4.3.1"},"reference-count":90,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,7,19]]},"abstract":"<jats:p>\n            Imipenem (IMI)\/cilastatin\/relebactam (REL) (I\/R) is a novel \u03b2-lactam\/\u03b2-lactamase inhibitor combination with expanded microbiologic activity against carbapenem-resistant non-\n            <jats:italic>Morganellaceae Enterobacterales<\/jats:italic>\n            (CR-NME) and difficult-to-treat (DTR)\n            <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n            . Relebactam, a bicyclic diazabicyclooctane, has no direct antimicrobial activity but provides reliable inhibition of many Ambler class A and class C enzymes.\n          <\/jats:p>","DOI":"10.1128\/aac.00256-22","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T13:15:49Z","timestamp":1655817349000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":38,"title":["New Perspectives on Antimicrobial Agents: Imipenem-Relebactam"],"prefix":"10.1128","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5184-1385","authenticated-orcid":true,"given":"J. Nicholas","family":"O\u2019Donnell","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0655","authenticated-orcid":true,"given":"Thomas P.","family":"Lodise","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2013.12.101"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-019-1522-7"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S325520"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00642-17"},{"key":"e_1_3_2_6_2","unstructured":"Anonymous. 2019. RECARBRIO\u2122 (imipenem cilastatin and relebactam) for injection for intravenous use. Merck Sharp & Dohme LLC Rahway NJ USA. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/r\/recarbrio\/recarbrio_pi.pdf. Accessed on February 1 2022."},{"key":"e_1_3_2_7_2","unstructured":"Anonymous. 2020. Recarbrio - EMEA\/H\/C\/004808 - N\/0010. European Medicines Agency Amsterdam The Netherlands. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/recarbrio-epar-product-information_en.pdf. Accessed on February 1 2022."},{"key":"e_1_3_2_8_2","volume-title":"The Clinical and Laboratory Standards Institute (CLSI) has published M100\u2014performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2005","unstructured":"Clinical and Laboratory Standards Institute. 2005. The Clinical and Laboratory Standards Institute (CLSI) has published M100\u2014performance standards for antimicrobial susceptibility testing, 31st ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"31"},{"key":"e_1_3_2_9_2","unstructured":"EUCAST. 2022. Clinical breakpoints\u2013breakpoints and guidance. https:\/\/www.eucast.org\/clinical_breakpoints\/."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00169-18"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.10.022"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-021-04363-7"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab320"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2021.115421"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piaa056"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa381"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02255-19"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.10.022"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa456"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab043"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02408-19"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.001142"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.10.004"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00573-18"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.01.025"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-021-01735-1"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106439"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab141"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00084-21"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2021.115327"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01432-20"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa353"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00757-20"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz354"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-019-03517-y"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02097-16"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02534-16"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2021.115568"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00280-18"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14204"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01411-17"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02577-17"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03706-14"},{"key":"e_1_3_2_44_2","first-page":"2197","article-title":"In vivo activity of human-simulated regimens of imipenem alone and in combination with relebactam against Pseudomonas aeruginosa in the murine thigh infection model","volume":"75","author":"Reyes S","year":"2020","unstructured":"Reyes S, Abdelraouf K, Nicolau DP. 2020. In vivo activity of human-simulated regimens of imipenem alone and in combination with relebactam against Pseudomonas aeruginosa in the murine thigh infection model. J Antimicrob Chemother 75:2197\u20132205.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz114"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01764-20"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.08.026"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02323-17"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05927-11"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02307-18"},{"key":"e_1_3_2_51_2","unstructured":"Anonymous. 2016. PRIMAXIN (imipenem and cilastatin) for injection for intravenous use. Merck Sharp & Dohme Corp. Whitehouse Station NJ USA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/050587s074lbl.pdf."},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro862"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_3_2_54_2","volume-title":"Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products (EMA\/CHMP\/594085\/2015).","author":"European Medicines Agency","year":"2016","unstructured":"European Medicines Agency. 2016. Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products (EMA\/CHMP\/594085\/2015). Committee for Medicinal Products for Human Use, London, UK."},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01659-18"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01269-15"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv132"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2210"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06113-11"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13158"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01971-18"},{"key":"e_1_3_2_62_2","volume-title":"PRIMAXIN (imipenem and cilastatin). US Prescribing information.","author":"Anonymous","year":"2016","unstructured":"Anonymous. 2016. PRIMAXIN (imipenem and cilastatin). US Prescribing information. Merck Sharp & Dohme Corp, Whitehouse Station, NJ, USA."},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00633-16"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx139"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa803"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz530"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2020.09.032"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab554"},{"key":"e_1_3_2_69_2","volume-title":"Community-acquired bacterial pneumonia: developing drugs for treatment, guidance for industry.","author":"US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research","year":"2014","unstructured":"US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research. 2014. Community-acquired bacterial pneumonia: developing drugs for treatment, guidance for industry. Center for Drug Evaluation and Research, Silver Spring, MD."},{"key":"e_1_3_2_70_2","volume-title":"Guidance for industry. Complicated intra-abdominal infections: developing drugs for treatment.","author":"US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research","year":"2018","unstructured":"US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research. 2018. Guidance for industry. Complicated intra-abdominal infections: developing drugs for treatment. Center for Drug Evaluation and Research, Silver Spring, MD."},{"key":"e_1_3_2_71_2","volume-title":"Guidance for industry. Complicated urinary tract infections: developing drugs for treatment.","author":"US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research","year":"2015","unstructured":"US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research. 2015. Guidance for industry. Complicated urinary tract infections: developing drugs for treatment. Center for Drug Evaluation and Research, Silver Spring, MD."},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-198510000-00009"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02203-19"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac097"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106196"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1306"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab311"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1799"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-021-04397-x"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-021-04197-3"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106595"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz433"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-57844-8"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2021.02.001"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1519"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2019.10.028"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky107"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00830-15"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.05.001"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00535-19"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz191"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00256-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00256-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T13:12:57Z","timestamp":1658236377000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00256-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":90,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7,19]]}},"alternative-id":["10.1128\/aac.00256-22"],"URL":"https:\/\/doi.org\/10.1128\/aac.00256-22","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]},"assertion":[{"value":"2022-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00256-22"}}